Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. BIOAF


Primary Symbol: V.BTI

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by JDavenporton Oct 01, 2022 11:10am
123 Views
Post# 34999322

RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

RE:RE:RE:RE:RE:RE:RE:Prothena and Management's ReportingHere's a question for you. Has any licensee or partner ever made a milestone payment? Which prompts the question, has any partner or licensee ever reached a milestone? Chiesi, in over two years, has never reached a developmental milestone? None?

If no partner or licensee has reached a milestone, have any given up trying to do so?

So you can say that Bioasis obviously needs more time but how does one reconcile that with the short timeline of the Janssen agreement and its reference to multiple programs? Why is Chiesi in its third year and still has not reported a developmental milestone? The original press release and the webcast talked about developmental, regulatory and commercial milestones. 

I've been asking these questions in one form or another since 2015.

jd
<< Previous
Bullboard Posts
Next >>